We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved an olanzapine/samidorphan ...

However, the opioid pathway, a heavily studied physiologic pathway inextricably intertwined with behaviour and reward, rarely receives attention within psychiatric practice. Although the opioid system ...

Please provide your email address to receive an email when new articles are posted on . Olanzapine/samidorphan combination treatment reduced weight gain across several subgroups of individuals at ...

The FDA approved the antipsychotic combination of olanzapine plus samidorphan (Lybalvi) for adults with schizophrenia or bipolar I disorder, drugmaker Alkermes announced on Tuesday. In schizophrenia, ...

schizophrenia Researchers report on the 52-week extension of the ENLIGHTEN-2 study that assessed the long-term safety and efficacy of treatment schizophrenia with olanzapine and samidorphan. Dual ...

In a poster presentation at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York, New York, May 10 to 12, researchers reported about an adjunctive ...

— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...

sad woman on couch An adjunctive buprenorphine/samidorphan combination seems beneficial for patients with major depressive disorder with inadequate response to ...